Intellia Therapeutics (NASDAQ:NTLA) Upgraded to Sell at StockNews.com

Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at StockNews.com to a “sell” rating in a research note issued to investors on Monday.

Other equities research analysts have also recently issued research reports about the stock. BMO Capital Markets lowered their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Morgan Stanley lowered Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $56.00 to $11.00 in a report on Monday, January 27th. William Blair reiterated a “neutral” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a report on Monday, November 18th. The Goldman Sachs Group restated a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Friday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $42.12.

Intellia Therapeutics Stock Down 6.3 %

Shares of NTLA stock traded down $0.64 on Monday, hitting $9.45. The stock had a trading volume of 2,998,270 shares, compared to its average volume of 3,289,680. Intellia Therapeutics has a one year low of $8.96 and a one year high of $33.28. The business has a 50 day moving average price of $10.85 and a 200 day moving average price of $15.55. The company has a market cap of $962.47 million, a PE ratio of -1.74 and a beta of 1.80.

Insider Buying and Selling at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 29,000 shares of company stock worth $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds have recently added to or reduced their stakes in NTLA. GF Fund Management CO. LTD. purchased a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $25,000. Sterling Capital Management LLC raised its position in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics in the fourth quarter valued at approximately $40,000. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics in the fourth quarter valued at approximately $43,000. Finally, Jones Financial Companies Lllp boosted its position in Intellia Therapeutics by 140.9% in the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.